Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium.
about
Oritavancin disrupts membrane integrity of Staphylococcus aureus and vancomycin-resistant enterococci to effect rapid bacterial killingReduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implicationsOritavancin: A New Lipoglycopeptide Antibiotic in the Treatment of Gram-Positive InfectionsNewer antibacterial drugs for a new century.Host-guest chemistry of the peptidoglycanSynthesis and evaluation of selected key methyl ether derivatives of vancomycin aglycon.Adenylate kinase release as a high-throughput-screening-compatible reporter of bacterial lysis for identification of antibacterial agents.Structural variations of the cell wall precursor lipid II and their influence on binding and activity of the lipoglycopeptide antibiotic oritavancin.Comparison of the efficacy and safety of oritavancin front-loaded dosing regimens to daily dosing: an analysis of the SIMPLIFI trial.Oritavancin activity against vancomycin-susceptible and vancomycin-resistant Enterococci with molecularly characterized glycopeptide resistance genes recovered from bacteremic patients, 2009-2010Oritavancin for acute bacterial skin and skin structure infections.Programming stress-induced altruistic death in engineered bacteriaSurface mediated cooperative interactions of drugs enhance mechanical forces for antibiotic action.Current and prospective treatments for multidrug-resistant gram-positive infections.Oritavancin: first global approval.Oritavancin, a single-dose, complete regimen, for the treatment of acute bacterial skin and skin structure infections.The times they are a-changin': new antibacterials for skin and skin structure infections.Pharmacological Basis of CD101 Efficacy: Exposure Shape Matters.Oritavancin: a review in acute bacterial skin and skin structure infections.Dalbavancin and Oritavancin: An Innovative Approach to the Treatment of Gram-Positive Infections.Lipoglycopeptide Antibacterial Agents in Gram-Positive Infections: A Comparative Review.Oritavancin: a long-acting antibacterial lipoglycopeptide.Targeting bactoprenol-coupled cell envelope precursors.Membrane Disruption and Enhanced Inhibition of Cell-Wall Biosynthesis: A Synergistic Approach to Tackle Vancomycin-Resistant Bacteria.Oritavancin Combinations with β-Lactams against Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant EnterococciComparative Pharmacodynamics of Single-Dose Oritavancin and Daily High-Dose Daptomycin Regimens against Vancomycin-resistant Enterococcus faecium Isolates in an In Vitro PK/PD Model of Infection.Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study.Prolonged Use of Oritavancin for Vancomycin-Resistant Enterococcus faecium Prosthetic Valve Endocarditis.Cell-penetrating peptide and antibiotic combination therapy: a potential alternative to combat drug resistance in methicillin-resistant Staphylococcus aureus.Antistaphylococcal activity of oritavancin and its synergistic effect in combination with other antimicrobial agents.Assessment of oritavancin serum protein binding across species.Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.Pharmacodynamics of a simulated single 1,200-milligram dose of oritavancin in an in vitro pharmacokinetic/pharmacodynamic model of methicillin-resistant staphylococcus aureus infection.Isolation and identification of lipopeptide antibiotics from Paenibacillus elgii B69 with inhibitory activity against methicillin-resistant Staphylococcus aureus.In vivo efficacy and synergistic interaction of 16α-hydroxycleroda-3, 13 (14) Z-dien-15, 16-olide, a clerodane diterpene from Polyalthia longifolia against methicillin-resistant Staphylococcus aureus.Successful Treatment of Methicillin Susceptible Staphylococcus aureus Osteomyelitis with Oritavancin.Synergistic effect of (+)-pinitol from Saraca asoca with β-lactam antibiotics and studies on the in silico possible mechanism.Rates of killing of methicillin-resistant Staphylococcus aureus by ceftaroline, daptomycin, and telavancin compared to that of vancomycin.Multiple-Dose Oritavancin Evaluation in a Retrospective Cohort of Patients with Complicated Infections.In vivo activity of oritavancin in animal infection models and rationale for a new dosing regimen in humans.
P2860
Q24606291-6F934365-CB5F-454A-A393-E8400891C24BQ24646677-54C044E3-CA4A-46F6-AA8B-64E55DD449EAQ26772897-5BF5B4C0-E8F0-4EBF-8E57-0D505DA45311Q30433333-8E9F9449-12AB-4602-B645-15B2112395DCQ34013593-474B5E01-4A0E-45A8-9DA6-108692EA9F33Q34308628-68526D0A-C13A-4F0C-9CEF-B031AA11D3A4Q34425938-76ED198E-AF23-447B-8EB4-CA51A00BE4D5Q34448260-9E639C14-1023-4B61-B741-5B9A288511C1Q35065786-F7EB9088-0946-40B0-982B-B338121203ECQ35806241-620E2CDA-CB7C-4060-89CC-94A9DE551AB5Q36086423-EE9F095D-BBC6-4B09-83A9-1C09F67D1AC3Q36493255-5F88A09B-F980-43B7-AD4A-CB946306E250Q37623139-F1FF36A3-3F9F-4E7E-93C7-A79BFD0F2AC0Q38123255-1A0406BB-F829-45D7-8AF1-8425B47F7912Q38252710-E55D758A-9DDD-4084-ACD3-01D0A9E2FF9DQ38347765-93DAB527-1C6D-435C-8A07-0A856B0BFEADQ38438503-276A39A1-250F-4FB8-836C-8F4A91B8620CQ38605120-3F54B273-5F58-4701-B940-E15B3FA65735Q38606618-A1AAFF31-1CC7-4825-BDFA-FDBC4101076FQ38615330-9AE4A0AB-191C-42F7-8AFE-BAFC99541A7AQ38646905-28BE9208-D07B-41AE-BDAC-2137ED7C2CC3Q38830176-D1014200-0314-4507-8CF8-B848E4C1EDA8Q38919751-CF0B1A79-416B-4EAF-930C-88191493D873Q38952894-E00BA934-114F-45CE-819C-89B75136F1F4Q39516822-83B21766-0C59-4254-995C-AB28C96A8CBCQ40103272-CD890FA7-0797-41F4-99E9-7A991148E429Q40187951-051947DC-7CFB-4A29-8FCC-CB85D98F0D19Q40201824-F249AE40-5C15-4B34-A2ED-89D5AEDEE6C2Q40808308-91E727B7-AD21-45B0-9522-CE78BA2ED881Q41810303-70AED9E9-26A7-4111-8F25-3E6C415C7875Q42076292-A6FC3E60-F795-4BEA-97FA-BB27F33B0760Q42111507-60A5E269-8F2F-42B4-8945-4DB341BDF035Q42530056-41C6F32E-71C6-493D-BCF7-28B4096ED931Q44171186-2F27A526-5AB6-4457-8D71-30F52BFE8A2CQ44687380-23FB35A0-FBF2-45D1-AF76-6DFFB436DAF9Q45059895-9A350AF6-1020-4C50-8E84-4CD25DB48D24Q47366193-73D2E838-D846-4D77-89EA-670E4776FF1FQ48667274-A495A812-8B7A-4188-950C-56210D1F5AB8Q50091622-FDD4432F-F003-43A8-A90B-F68A1A16E562Q51760113-32220648-57BF-406E-81BD-18F3BED6E368
P2860
Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Time-kill kinetics of oritavan ...... alis and Enterococcus faecium.
@en
Time-kill kinetics of oritavan ...... alis and Enterococcus faecium.
@nl
type
label
Time-kill kinetics of oritavan ...... alis and Enterococcus faecium.
@en
Time-kill kinetics of oritavan ...... alis and Enterococcus faecium.
@nl
prefLabel
Time-kill kinetics of oritavan ...... alis and Enterococcus faecium.
@en
Time-kill kinetics of oritavan ...... alis and Enterococcus faecium.
@nl
P2093
P2860
P356
P1476
Time-kill kinetics of oritavan ...... calis and Enterococcus faecium
@en
P2093
Adam Belley
Francis F Arhin
Geoffrey A McKay
Ingrid Sarmiento
Sylvain Beaulieu
Thomas Parr
P2860
P304
P356
10.1093/JAC/DKP126
P407
P50
P577
2009-04-15T00:00:00Z